T. Rowe Price Associates, Inc.
T. Rowe Price Associates, Inc. focuses its venture capital efforts on identifying innovative private companies with the potential for durable long-term growth, often taking a long-term view and seeking higher expected returns due to the inherent risks. Their strategy involves rigorous fundamental research to uncover companies that can scale from early-stage to successful public entities, with some strategies also incorporating environmental, social, and governance (ESG) factors and alignment with UN Sustainable Development Goals.
Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Average disclosed round size is $368.1M (across 53 rounds with reported amounts).
Portfolio
54
Fund Size
$1B
Top Stage
Growth
Last 12 Mo
2
Team
Greg Dunham
Founder
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Hadrian | Unknown | — | Jan 2026 |
 Ramp | Growth | $500M | Jul 2025 |
 Nuro | Series E | $106M | Apr 2025 |
 Aktis Oncology | Series B | $175M | Sep 2024 |
 Clio | Series F | $900M | Jul 2024 |
 Databricks | Growth | $500M | Nov 2023 |
 Avalyn Pharma Inc. | Series C | $175M | Sep 2023 |
 Generate:Biomedicines | Series C | $273M | Sep 2023 |
| RRapport Therapeutics | Series B | $150M | Aug 2023 |
| CCARGO Therapeutics, Inc. | Series A | $200M | Mar 2023 |
 Odyssey Therapeutics, Inc. | Series B | $168M | Oct 2022 |
 Celonis | Series D | $1B | Aug 2022 |
 FLEXE | Series D | $119M | Jul 2022 |
 Sionna Therapeutics | Series B | $111M | Apr 2022 |
 Freenome | Series D | $300M | Dec 2021 |
 Color | Series E | $100M | Nov 2021 |
| Nuro | Series D | $600M | Nov 2021 |
 Nodes & Links | Series A | $11M | Jun 2021 |
 Caris Life Sciences | Growth | $830M | May 2021 |
 SecurityScorecard | Series E | $180M | Mar 2021 |
 Instacart | Growth | $265M | Mar 2021 |
 UiPath | Series F | $750M | Feb 2021 |
| Databricks | Series G | $1B | Feb 2021 |
 Sila Nanotechnologies | Series F | $590M | Jan 2021 |
 DELFI Diagnostics, Inc. | Series A | $100M | Jan 2021 |
Top Co-Investors
Last updated: 15 April 2026